References
- Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;150(4):262–2674. DOI:https://doi.org/10.7326/0003-4819-159-4-201308200-00007.
- Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39(5):717–725.
- Chrysant SG. Promising cardiovascular and blood pressure effects of SGLT2 inhibitors: a new class of antidiabetic drugs. Drugs Today. 2017;53(3):191–202. DOI:https://doi.org/10.1358/dot.2017.53.3.2555985.
- Dziuba J, Alperin P, Racketa J, et al. Modeling SGLT2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab. 2014;16(7):628–635. DOI:https://doi.org/10.1111/dom.12261.
- Arnott C, Li Q, Kang A, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9(3):e014908. DOI:https://doi.org/10.1161/JAHA.119.014908.
- Verma S, Garg A, Yan AT, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care. 2016;39(12):e212–e213.
- Uthman L, Baartscheer A, Schumacher CA, et al. Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients. Front Physiol. 2018;9:1575.
- Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT 2) inhibitors. J Am Coll Cardiol Basic Trans Sci. 2020;5:632–644.
- Shi L, Zhou D, Wang S, et al. Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload. Am J Hypertens. 2019;32(5):452–459. DOI:https://doi.org/10.1093/ajh/hpz016.
- Lee HC, Shiou YL, Jhuo SJ, et al. The sodium glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol. 2019;18(1):45. DOI:https://doi.org/10.1186/s12933-019-0849-6.
- Packer M. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. Cardiovasc Res. 2021;117(1):74–84. DOI:https://doi.org/10.1093/cvr/cvaa064.
- Packer M. Autophagy stimulation and intracellular sodium reduction as mechanisms of the cardioprotective effect of sodium-glucose cotransporter 2 inhibitors. Eur J Heart Fail. 2020;22(4):618–628. DOI:https://doi.org/10.1002/ejhf.1732.
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 377(7): 644–657. 2017. https://doi.org/10.1056/NEJMoa1611925.
- Wiviott SD, Raz I, Bonaca MC, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 380(4): 347–357. 2019. https://doi.org/10.1056/NEJMoa1812389.
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 373(22): 2117–2128. 2015. https://doi.org/10.1056/NEJMoa1504720. .
- Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 383(15): 1425–1435. 2020. https://doi.org/10.1056/NEJMoa2004967.
- Rehman SU, Rahman F. Evidence-based clinical review on cardiovascular benefits of SGLT2 (sodium-glucose co-transporter type 2) inhibitors in type 2 diabetes mellitus. Cureus. 2020;12(8):e9655.
- Verma S, Mazer CD, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with type 1 diabetes mellitus and coronary artery disease. The EMPA-HEART cardiolink-6 randomized clinical trial. Circulation. 2019;140(21):1693–1702. DOI:https://doi.org/10.1161/CIRCULATIONAHA.119.042375.
- Yu YW, Zhao XM, Wang YH, et al. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Cardiovasc Diabetol. 2021;25(1):25. DOI:https://doi.org/10.1186/s12933-020-01209-y.
- Lee MMY, Jhund PS, Petrie MC, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516–525. DOI:https://doi.org/10.1161/CIRCULATIONAHA.120.052186.
- Shim CY, Seo J, Cho I, et al. Randomized, controlled trial to evaluate the effect of dapagliflozin on left ventricular diastolic function in patients with type 2 diabetes mellitus. The IDDIA trial. Circulation. 2021;143(5):510–512. DOI:https://doi.org/10.1161/CIRCULATIONAHA.120.051992.
- Tsimihodimos V, Filippas-Ntekouan S, Elisaf M. SGLT1 inhibitors: pros and cons. Eur J Pharmacol. 2018;638:153–156.
- Ali Sayour A, Ruppet M, Olah A, et al. Effects of SGLT2 inhibitors beyond glycemic control-focus on myocardial SGLT1. Int J Mol Sci. 2021;22(18):9852. DOI:https://doi.org/10.3390/ijms22189852.
- Li Y, Xu G. Sodium glucose cotransporter 1 (SGLT1) inhibitors in cardiovascular protection: mechanism progresses and challenges. Pharmacol Res. 2022;176:106049.
- Anker SD, Butler J, Filipatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. DOI:https://doi.org/10.1056/NEJMoa2107038.
- Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Med. 2021;27(11):1954–1960. DOI:https://doi.org/10.1038/s41591-021-01536-x.
- Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 384(2): 117–128. 2021. https://doi.org/10.1056/NEJMoa2030183.
- Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 384(2): 129–139. 2021. https://doi.org/10.1056/NEJMoa2030186.
- Bertoluci MC, Rocha VZ, Khan MI. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr. 2017;9:1–13.
- Pawlos A, Broncel M, Wozniak E, et al. Neuroprotective effect of SGLT2 inhibitors. Molecules. 26(23): 7213. 2021. https://doi.org/10.3390/molecules26237213.
- Nguyen TT, Ta QTH, Nguyen TTD, et al. Type 3 diabetes and its role implications in alzheimer’s disease. Int J Mol Sci. 2020;21(9):3165. DOI:https://doi.org/10.3390/ijms21093165.
- Hierro-Bujalance C, Infante-Gracia C, Marco A, et al. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes. Alzheimer’s Res Ther. 2020;4:1–13.
- Zhang C, Zhang X, Wang P, et al. Effect of SGLT2 inhibitors on risk of stroke in diabetes: a meta-analysis. Cerebrovasc Dis. 2022;31:1–9. DOI:https://doi.org/10.1159/000521782.
- Guo M, Ding J, Li J, et al. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: a systematic review and meta-analysis. Dibets Obes Metab. 2018; 20(8) 1977–1982. https://doi.org/10.1111/dom.13295 .
- Kaplan A, Abidi E, El-Yazbi A, et al. Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. Heart Fail Rev. 2018;23(3):419–437. DOI:https://doi.org/10.1007/s10741-017-9665-9.
- Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens. 2014;16(12):875–882. DOI:https://doi.org/10.1111/jch.12425.
- Townsend RR, Machin I, Ren J, et al. Reduction in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension. J Clin Hypertens. 2016;18(1):43–52. DOI:https://doi.org/10.1111/jch.12747.
- Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2018;38(3):420–428. DOI:https://doi.org/10.2337/dc14-1096.
- Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262–265. DOI:https://doi.org/10.1016/j.jash.2014.01.007.
- Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 1999;15(6):412–426.
- Weber MA, Mansfield TA, Cain VA, et al. Blood pressure and glycemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomized, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4(3):211–220. DOI:https://doi.org/10.1016/S2213-8587(15)00417-9.
- Lambers Heerspink HJ, de Zeeuw D, Wie L, et al. Dapagliflozin a glucose- regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853–862. DOI:https://doi.org/10.1111/dom.12127.
- Hallow KM, Helmlinger G, Greasley PJ, et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20(3):479–487. DOI:https://doi.org/10.1111/dom.13126.
- Briasoulis A, Androulakis E, Christofides T, et al. The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Fail Rev. 2016;21(2):169–176.
- Innantuori F, de Maranon AM, Diaz-Morales N, et al. The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an atioxidant response in leukocytes. J Clin Med. 2019;8(11):1814.
- Heerspink HJL, Perco P, Mulder S, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019;62(7):1154–1166. DOI:https://doi.org/10.1007/s00125-019-4859-4.
- Cannon CP, Perkovic V, Agarwal R, et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes Mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c ≤ 7%: results from the CREDENCE trial<7%. Circulation. 2019;141(5):407–410. DOI:https://doi.org/10.1161/CIRCULATIONAHA.119.044359.
- Perkovic V, Jardene MJ, Neal S, et al. Canaglflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. DOI:https://doi.org/10.1056/NEJMoa1811744.
- Connelly KA, Zhang Y, Vistram A, et al. Empagliflozin improves diastolic function in a non-diabetic rodent model of heart failure with preserved ejection fraction. J Am Coll Cardiol Basic Trans Sci. 2019;4. 27–37.
- Pietschner R, Kolwelter J, Bosch A, et al. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. Cardiovasc Diabetol. 2021;20(1):20219. DOI:https://doi.org/10.1186/s12933-021-01410-7.
- Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME Trial: a “thrifty substrate” hypothesis. Diabetes Care. 2016;39(7):1108–1114.
- Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucoseSodium–Glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190–1195. DOI:https://doi.org/10.2337/db15-1356.
- Aubert G, Martin OJ, Horton JL, et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016;133(8):698–705. DOI:https://doi.org/10.1161/CIRCULATIONAHA.115.017355.
- Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study?.Study? A unifying hypothesis. Diabetes Care. 2016;39(7):1115–1122.
- Ferrannini E, Mark M, Mayou E. CardiovascularCV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate hypothesis” Hypothesis. Diabetes Care. 2016;39(7):1108–1114.
- Lopaschuk GD, Ussher JR, Folmes CDLCD, et al. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207–258.
- Neubauer S. The failing heart-an Heart — an engine out of fuel. N Engl J Med. 2007;356(11):1140–1151114- 1151.
- Bedi KC, Snyder NW, Bradimarto J, et al. Evidence for intramyocardial disruption of lipid metabolism and increased intramyocardial ketone utilization in advanced heart failure. Circulation. 2016;133:706–716.
- Horton JL, Davidson MT, Kurishima CG, et al. The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. JCI Insight. 2019;4(4):e124079.
- Chiba Y, Yamada T, Tsukita S, et al. Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice. PloS One. 2016;11(3):e0150756. DOI:https://doi.org/10.1371/journal.pone.0150756.
- Jordan J, Tank J, Heusser K, et al. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. J Am Soc Hypertens. 2017;11(9):604–612.
- Matthews VB, Elliott RH, Rudnicka C, et al. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens. 2017;35(10):2059–2068.
- Daubner SC, Lee T, Wang S. Tyrosine hydroxylate and regulation of dopamine synthesis. Arch Biochem Biophys. 2011;508(1):1–12.
- Byrne NJ, Parajuli N, Levasseut JL, et al. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. J Am Coll Cardiol Basic Trans Sci. 2017;2. 347–354.
- Kang S, Verma S, Hassanabad AF, et al. Direct effect of empagliflozin on extracellular matrix remodeling in human cardiac fibroblasts: novel translational clues to explain EMPA-REG OUTCOME results. Can J Cardiol. 2020;36(4):543–553. DOI:https://doi.org/10.1016/j.cjca.2019.08.033.
- Kusaka H, Koibuchi N, Hasgawa Y, et al. Enpagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016;15(1):157. DOI:https://doi.org/10.1186/s12933-016-0473-7.
- Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infracted rat hearts. Free Radic Biol Med. 2017;104:298–310.
- Sano M. Hemodynamic effects of sodium-glucose cotransporter 2 inhibitors. J Clin Med Res. 2017;9(6):457–460.
- Lin B, Koibuchi N, Hasegawa Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13(1):148. DOI:https://doi.org/10.1186/s12933-014-0148-1.
- Lee MMY, Jhund PS, Petrie MC, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, in heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516–525.
- Kahn AM, Lichtenberg RA, Allen JC, et al. Insulin-Stimulated Glucose Transport Inhibits Ca2+++ Influx and Contraction in Vascular Smooth Muscle. Circulation. 1995;92(6):1597–1603. DOI:https://doi.org/10.1161/01.CIR.92.6.1597.
- Berna N, Arnould T, Remacle J, et al. Hypoxia-induced increase in intracellular calcium concentration in endothelial cells: role of the Na+-glucose cotransporter. J Cell Biochem. 2001;84(1):115–131. DOI:https://doi.org/10.1002/jcb.1271.
- Salim HM, Fukuda D, Yagi S, et al. Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse. Frnt Cardiovasc Med. 2016;3. 43.
- Lastra G, Manrique C. Perivascular adipose tissue, inflammation and insulin resistance: link to vascular dysfunction and cardiovascular disease. Horm Moll Biol Clin Invest. 2015;22:19–26.
- Xu J, Hirai T, Koya D, et al. Effects of SGLT2 inhibitors on atherosclerosis: lessons from cardiovascular clinical outcomes in type 2 diabetic patients and basic researches. J Clin Med. 2022;11(1):137. DOI:https://doi.org/10.3390/jcm11010137.
- Yurista SR, Sillje HH, Oberdorf-Mass SU, et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. 2019;21(7):862–873. DOI:https://doi.org/10.1002/ejhf.1473.
- Nielsen R, Moller N, Gormsen LC, et al. Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in heart failure patients. Circulation. 2019;139(18):2129–2141. DOI:https://doi.org/10.1161/CIRCULATIONAHA.118.036459.
- Mazer CD, Hara GM, Connelly PW, et al. Effect of empagliflozin on erythropoietin levels, iron stores and red blood cell morphology in patients with type 2 diabetes and coronary artery disease. Circulation. 2020;141(8):704–707. DOI:https://doi.org/10.1161/CIRCULATIONAHA.119.044235.
- Kotecha D, Ngo K, Walters JA, et al. Erythropoetin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J. 2011;161(5):822–831. DOI:https://doi.org/10.1016/j.ahj.2011.02.013.
- Baker HE, Kiel AM, Luebbe ST, et al. Inhibition of sodium-glucose cotransporter 2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization. Basic Res Cardiol. 2019;21:357–365.
- McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. DOI:https://doi.org/10.1056/NEJMoa1911303.
- Bay J, Kohlaas M, Maack C. Intracellular Na+ and cardiac metabolism. 2013;J Moll Cell Cardiol. 61:2–27. https://doi.org/10.1016/j.yjmcc.2013.05.010
- Kohlhaas M, Liiu T, Knapp A, et al. Elevated cytosolic Na + increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. Circulation. 2010;121(14):1606–1613. DOI:https://doi.org/10.1161/CIRCULATIONAHA.109.914911.
- Baartscheer A, Schumacher CA, Wust RC, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017;60(3):568–573. DOI:https://doi.org/10.1007/s00125-016-4134-x.
- Uthman L, Baartscheer A, Bleijlevens B, et al. Class effect of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018;61(3):722–726. DOI:https://doi.org/10.1007/s00125-017-4509-7.
- Karg MV, Bosch A, Kannenkeril D, et al. SGLT2-inhibition with dapagliflozin reduces tissue sodium content: a randomized controlled trial. Cardiovasc Diabetol. 2018;5:17.
- Bartero E, Prates Roma L, Ameri P, et al. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res. 2018;114(1):12–18. DOI:https://doi.org/10.1093/cvr/cvx149.
- Packer M, Anker SD, Butler J, et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2(9):1025–1029. DOI:https://doi.org/10.1001/jamacardio.2017.2275.
- Pedan E, Landau M. Sodium-proton (Na+/H+) antiporters: properties and roles in health and disease. Met Ions Life Sci. 2016;16:391–458.
- Girardi AC, Di Sola F. Deciphering the mechanisms of the Na+/H+ exchanger-3 regulation in organ dysfunction. Am J Physiol Cell Physiol. 2012;302(11):C1569–1587 .
- Xu C, Wang W, Zhong J, et al. Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting Autophagy in immune cells. Biochem Pharmacol. 2018;152:45–59.
- Aragon-Herrera A, Faijoo-Bandin S, Otero Santiago M, et al. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 2019;170:113677.
- Shirakaba A, Zhai P, Ikeda Y, et al. Drp 1-dependent mitochondrial autophagy plays a protective role against pressure overload-induced mitochondrial dysfunction and heart failure. Circulation. 2016;133(13):1249–1263. DOI:https://doi.org/10.1161/CIRCULATIONAHA.115.020502.
- Nishida K, Taneike M, Otsu K. The role of autophagic degradation in the heart. 2015;J Moll Cell Cardiol. 78:73–79. https://doi.org/10.1016/j.yjmcc.2014.09.029
- Mizuno M, Kuno A, Yano T, et al. Empagliflozin normalizes the size and number of mitochondria and prevents reduction of mitochondrial size after myocardial infarction in diabetic hearts. Physiol Rep. 2018;6(12):e13741. DOI:https://doi.org/10.14814/phy2.13741.
- Deretic V, Levine B. Autophagy balances inflammation in innate immunity. Autophagy. 2018;14(2):243–251.
- Zhou H, Wang S, Zhou P, et al. Empagliflozin rescues diabetic myocardial microvascular injury via AMK-mediated inhibition of mitochondrial fusion. Redox Biol. 2018;15:335–346.
- Mancini SJ, Boyd D, Katwan OJ, et al. Canagliflozin inhibits interleukin 1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and independent mechanisms. Sd Rep. 2018;8. 5276.
- Hawley SA, Ford BJ, Smith BK, et al. The Na+/ glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65(9):2784–2794. DOI:https://doi.org/10.2337/db16-0058.
- Bishop T, Ratcliffe PJ. HIF hydrolase pathways in cardiovascular physiology and medicine. Circ Res. 2015;117(1):65–79.
- Teo YH, Teo YN, Syn NL, et al. Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. JAMA. 2021;10:e019463.
- Dekkers CCJ, Sjostrom CD, Greasley PJ, et al. Effects of sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes Metab. 2019;12(12):2667–2673. DOI:https://doi.org/10.1111/dom.13855.
- Tanaka A, Shimabukuro M, Okada Y, et al. Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial. Cardiovasc Diabetol. 2021;20(1):105. DOI:https://doi.org/10.1186/s12933-021-01295-6.
- Matsushima S, Sadoshima J. The role of sirtuins in cardiac disease. Am J Physiol Heart Circ Physiol. 2015;309(9):H1375–H1389 .
- Jiang K, Xu Y, Wang D, et al. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Prot Cell. 2021 Jan 8. https://doi.org/10.1007/sw13238-00809-4.